Use of In-Home Non-Stress Monitoring Device for Fetal Monitoring: A Nonsignificant Risk (NSR) Device Study
Sponsor: Nestmedic Spolka Akcyjna
Trial Details
| Condition | Pregnancy, Fetal Monitoring |
| Intervention | PregnaOne System |
| Phase | NA |
| Status | Completed |
| Participants | 71 |
| Est. Completion | 30 Jan 2026 |
| Last Updated | 20 Apr 2026 |
Primary Outcome
Agreement Between PregnaOne System and Comparator Device (INVU System) for Fetal Heart Rate (fHR) Measurements; Agreement Between PregnaOne System and Comparator Device (INVU System) for Uterine Muscle Activity Measurements; Percent of Participants Who Obtain a Quality Maternal Pulse Rate (mPR) Recording; Percent of Participants Who Successfully Complete a Self-Monitoring Session; Agreement Between PregnaOne System and Comparator for Fetal Heart Rate (fHR); Agreement Between PregnaOne System and Comparator for Uterine Muscle Activity
Eligibility Criteria
Inclusion Criteria
Inclusion Criteria: * Able to independently read and understand written and spoken English and willing to provide written informed consent and comply with all instructions required by the study protocol. * Female aged 22 years or older. * Estimated gestational age between 32 and 41 weeks. * Singleton gestation. * Pre-pregnancy or first prenatal visit BMI \< 40 kg/m². * Able and willing to undergo fetal monitoring sessions in a simulated home environment at the study site. * Women who do not meet the gestational age criterion at the screening visit but will meet it by the study visit (within two weeks) may be enrolled. Exclusion Criteria: * In active labor or in the delivery room during labor. * Requires hospitalization or life support. * Any contraindications for cardiotocography (CTG) monitoring. * Severe hypertension (≥160/110 mmHg measured twice, 15 minutes apart). * Known allergy to latex, ultrasound (US) gel, or ECG gel. * Skin conditions (e.g., edema, erythema, irritation, infection, lesions, or open wounds) at contact points for the Pregnabit Pro or comparator devices. * Implanted electronic devices (e.g., pacemaker, stimulator, defibrillator, pump). * Members of vulnerable populations other than pregnant women (e.g., minors, wards of the state, cognitively impaired individuals, prisoners, or institutionalized persons).
Trial Sites
Countries
This content is for educational purposes for healthcare professionals only and does not constitute clinical advice. Clinical decisions should be based on individual patient assessment, current guidelines, and appropriate specialist consultation. Editorial Standards · Privacy Policy · Terms of Service